Medivir in brief

Medivir is a specialty pharmaceutical company with unique positioning on the Nordic market. A momentous step in the company’s development was taken in 2011 through the acquisition of BioPhausia. Now, Medivir is a more complete pharmaceutical company, which combines successful research operations in infectious diseases with a Nordic sales organization that generates yearly sales of some SEK 500 m.

Medivir—a Nordic pharmaceutical company on the advance

BioPhausia A commercial portfolio currently generating annualized sales of some SEK 500 m.

Xerclear® Successfully taken a product all the way from original idea to market.

R&D Pharmaceutical research and development focusing on infectious diseases and with specialist competence in the segments of proteases and polymerases.

TMC435 and Hepatitis C Strong positioning in the hepatitis C segment with one of the most promising CDs in clinical phase III.